MX2021012581A - Métodos para cuantificar el inhibidor funcional de la c1 esterasa (fc1-inh). - Google Patents

Métodos para cuantificar el inhibidor funcional de la c1 esterasa (fc1-inh).

Info

Publication number
MX2021012581A
MX2021012581A MX2021012581A MX2021012581A MX2021012581A MX 2021012581 A MX2021012581 A MX 2021012581A MX 2021012581 A MX2021012581 A MX 2021012581A MX 2021012581 A MX2021012581 A MX 2021012581A MX 2021012581 A MX2021012581 A MX 2021012581A
Authority
MX
Mexico
Prior art keywords
inh
methods
quantitation
functional
esterase inhibitor
Prior art date
Application number
MX2021012581A
Other languages
English (en)
Inventor
Guodong Zhang
Jiang Wu
Priya Sethu Chockalingam
Zhiwei Zhou
Yongquan Lai
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021012581A publication Critical patent/MX2021012581A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21042—Complement subcomponent C1s (3.4.21.42)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

En la presente se proporcionan métodos para la cuantificación de fC1-INH a partir de una mancha de sangre seca. Dichos métodos pueden comprender aplicar y secar una muestra de sangre en un miembro de soporte, extraer proteínas de la muestra de sangre seca y medir el nivel de fC1-INH en las proteínas extraídas.
MX2021012581A 2019-04-16 2020-04-15 Métodos para cuantificar el inhibidor funcional de la c1 esterasa (fc1-inh). MX2021012581A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962834461P 2019-04-16 2019-04-16
US201962932011P 2019-11-07 2019-11-07
PCT/US2020/028205 WO2020214638A1 (en) 2019-04-16 2020-04-15 Methods for quantitation of functional c1 esterase inhibitor (fc1-inh)

Publications (1)

Publication Number Publication Date
MX2021012581A true MX2021012581A (es) 2021-12-10

Family

ID=70617205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012581A MX2021012581A (es) 2019-04-16 2020-04-15 Métodos para cuantificar el inhibidor funcional de la c1 esterasa (fc1-inh).

Country Status (13)

Country Link
US (1) US11754570B2 (es)
EP (1) EP3956667B1 (es)
JP (1) JP2022529265A (es)
KR (1) KR20210153097A (es)
CN (1) CN114402200A (es)
AU (1) AU2020258869A1 (es)
BR (1) BR112021020751A2 (es)
CA (1) CA3137014A1 (es)
CO (1) CO2021014146A2 (es)
IL (1) IL287294A (es)
MX (1) MX2021012581A (es)
TW (1) TW202104900A (es)
WO (1) WO2020214638A1 (es)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE15387T1 (de) 1980-09-30 1985-09-15 Cornell Res Foundation Inc Verfahren zum bestimmen von enzym-inhibitorkomplexen.
US4849353A (en) 1980-09-30 1989-07-18 Cornell Research Foundation, Inc. Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
JPH0754323B2 (ja) 1988-10-17 1995-06-07 三洋化成工業株式会社 免疫測定法および免疫測定試薬
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CN1057607C (zh) 1995-12-04 2000-10-18 广州市博普生物技术有限公司 一种双功能层析材料及制备方法和应用
JP2003505678A (ja) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
ATE382635T1 (de) 2000-01-31 2008-01-15 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
DE60141171D1 (de) 2000-11-27 2010-03-11 Intelligent Medical Devices Ll Klinische intelligente diagnostische vorrichtungen und verfahren
AU2003244516A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
EP1649064B1 (en) 2003-07-17 2011-06-01 Pacific Edge Biotechnology Limited Markers for detection of gastric cancer
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7459564B2 (en) 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
CA2630838A1 (en) 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7923240B2 (en) 2006-03-31 2011-04-12 Intel Corporation Photo-activated field effect transistor for bioanalyte detection
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
NZ596471A (en) 2007-01-16 2013-11-29 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US8283319B2 (en) 2007-02-12 2012-10-09 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
EP2356457B1 (en) 2008-10-13 2018-05-16 Xeptagen SPA Method for the preparation of immunoconjugates and use thereof
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
US20110140706A1 (en) 2009-05-07 2011-06-16 Groves John T Particle-Based Electrostatic Sensing and Detection
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
CN105452860B (zh) 2013-01-20 2019-08-02 戴埃克斯有限公司 Pkal-介导的病症的评估、测定和治疗
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
US20200340987A1 (en) 2019-02-21 2020-10-29 Dyax Corp. Lateral flow immunoassay for measuring functional c1-esterase inhibitor (c1-inh) in plasma samples

Also Published As

Publication number Publication date
WO2020214638A1 (en) 2020-10-22
JP2022529265A (ja) 2022-06-20
EP3956667C0 (en) 2024-03-13
US20200348311A1 (en) 2020-11-05
CA3137014A1 (en) 2020-10-22
TW202104900A (zh) 2021-02-01
AU2020258869A1 (en) 2021-11-25
US11754570B2 (en) 2023-09-12
BR112021020751A2 (pt) 2021-12-14
EP3956667A1 (en) 2022-02-23
KR20210153097A (ko) 2021-12-16
CO2021014146A2 (es) 2021-10-29
EP3956667B1 (en) 2024-03-13
IL287294A (en) 2021-12-01
CN114402200A (zh) 2022-04-26

Similar Documents

Publication Publication Date Title
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
WO2007024609A3 (en) Translation quality quantifying apparatus and method
DE60028732D1 (de) Verfahren zur erhaltung der dns-integrität
DK2126586T3 (da) Direkte bestemmelse af vitamin D i serum eller plasma
DK0804163T3 (da) Forbedret fremgangsmåde til stabilisering af biologiske stoffer under tørring og efterfølgende opbevaring samt præparater deraf
WO2004021395A3 (en) Method, system, and device for performing quantitative analysis using an ftms
ATE494548T1 (de) Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
JP2019507341A5 (es)
CA2798517A1 (en) Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
JP2021503610A5 (es)
ATE325203T1 (de) Nachweis und identifikation von bakteriengruppen
MX2020010315A (es) Ensayos sandwich de colocalizacion por enlace.
DK1516188T3 (da) Fremgangsmåde til påvisning og fjernelse af endotoksin
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
MX2021012581A (es) Métodos para cuantificar el inhibidor funcional de la c1 esterasa (fc1-inh).
EP4276201A3 (en) Detecting babesia species nucleic acid in a sample
AR115670A1 (es) Composiciones y procedimientos para la detección de ácido nucleico de especies de plasmodium
EP3884281A4 (en) METHOD FOR IDENTIFYING AN UNKNOWN BIOLOGICAL SAMPLE FROM MULTIPLE ATTRIBUTES
EA200602088A1 (ru) Способ стабилизации пептидов
WO2005091199A3 (en) A method for identifying unknown proteins by a two-dimensional step and the use of markers
MX2020001818A (es) Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra.
EP4040153A4 (en) PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE
EA201401335A1 (ru) Способ определения продуктов деградации пептидов из протеолитического каскада в образцах крови
AR118701A1 (es) Métodos para cuantificar el inhibidor de esterasa c1 funcional (fc1-inh)